Five Korean Drugmakers Seek To Invalidate Boehringer's Diabetes Patent At KIPTAB on August 15, 2025 Boehringer Ingelheim patent Chong Kun Dang Hanmi Huons Diabetes treatment patent Empagliflozin SGLT2 inhibitor KIPTAB patent invalidation Korean pharma companies +